Clinical Efficacy and Safety Analysis of Immunotherapy in Patients With Advanced Esophageal Cancer
Objective To explore the clinical efficacy and safety of immunotherapy in the treatment of advanced esophageal cancer.Methods A total of 78 patients with advanced esophageal cancer who received chemotherapy and immunotherapy(using carrilizumab)in Tengzhou Workers'Hospital from July 2020 to December 2022 were included.All patients were randomly divided into a chemotherapy group(n=31,albumin paclitaxel+cisplatin chemotherapy)and a combination therapy group(n=47,calilizumab combined with albumin paclitaxel+cisplatin chemotherapy).Progression-free survival(PFS),overall survival(OS)and objective response rate were compared between the two groups.ORR,disease control rate(DCR),common adverse reactions,etc.,and analyzed and compared the data of various indicators.Results The mean follow-up time was(15.70±0.32)months.The objective response rate(22.58%)and disease control rate(48.39%)in the chemotherapy group were lower than those in the combined treatment group(46.81%and 53.19%),and the difference was statistically significant(P<0.05).The ratio of adverse reactions between the two groups showed that the incidence of adverse reactions in combined treatment group(32.26%)was lower than that in chemotherapy group(64.52%),and the difference was statistically significant(P<0.05).Conclusion In the treatment of patients with advanced esophageal cancer,the application of immunotherapy can prolong the survival period,and the patients are well tolerated.Meanwhile,the study results of this paper provide reference content for the formulation of the standard of immunotherapy in the later stage of advanced esophageal cancer.
万方数据
维普
